Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
13 p, 449.0 KB Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma / Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ; Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ; Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Leleu, Xavier (CHU de Poitiers) ; Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ; Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ; Touzeau, Cyrille (Université de Nantes) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Paner, Agne (Rush University Medical Center) ; Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ; Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ; Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ; Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ; Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ; Thuresson, Sara (Oncopeptides AB) ; Thuresson, Marcus (Oncopeptides AB) ; Byrne, Catriona (Oncopeptides AB) ; Harmenberg, Johan (Oncopeptides AB) ; Bakker, Nicolaas A. (Oncopeptides AB) ; Mateos, M. V (Hospital Clínico Universitario (Salamanca))
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. [...]
2021 - 10.1200/JCO.20.02259
Journal of Clinical Oncology, Vol. 39 Núm. 7 (january 2021) , p. 757-767  

Vegeu també: autors amb noms similars
1 Laubach, Jacob
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.